Restless legs syndrome, periodic limb movements in sleep, and depression

Sleep

Volumn 28, Issue 7, 2005, Pages 891-898

  Picchietti, Daniel ^a,c   Winkelman, John W ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Antidepressants; Depression; Fatigue; Periodic limb movement disorder; Periodic limb movements in sleep; Restless legs syndrome; Sleep disorder

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUOXETINE; LITHIUM; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

CLINICAL FEATURE; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; FATIGUE; HUMAN; MYOCLONUS; PERIODIC LIMB MOVEMENT DISORDER; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; QUESTIONNAIRE; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; SEROTONIN SYNDROME; SLEEP DISORDER; SYMPTOM;

DEPRESSION; HUMANS; NOCTURNAL MYOCLONUS SYNDROME; PREVALENCE; RESTLESS LEGS SYNDROME; SLEEP;

EID: 22244444514     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Willis T, Eugenius P. The London practice of physick. London,: Bassett, Dring, Harper, and Crook; 1692:680.
2. Ekbom KA. Restless legs syndrome. Neurology 1960;10:868-73.
3. Earley CJ. Clinical practice. Restless legs syndrome. N Engl J Med 2003;348:2103-9.
4. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
5. Restless Legs Syndrome, Detection and Management in Primary Care: National Institutes of Health, 2000. Available at: www.nhl-bi.nih.gov/health/ prof/sleep/rls_gde.htm. Accessed on March 30, 2005.
6. Restless Legs Syndrome Foundation Medical Bulletin, 2004. Available at: http://www.rls.org/literature/bulletin.html. Accessed on March 30, 2005.
7. Recording and scoring leg movements. The Atlas Task Force. Sleep 1993;16:748-59.
8. International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
9. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61-5.
10. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916-22.
11. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999;22:970-99.
12. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-83.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000. p. 356.
14. Jackson JL, DeZee K, Berbano E. Can treating depression improve disease outcomes? Ann Intern Med 2004;140:1054-6.
15. Yue W, Hao W, Liu P, Liu T, Ni M, Guo Q. A case-control study on psychological symptoms in sleep apnea-hypopnea syndrome. Can J Psychiatry 2003;48:318-23.
16. Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res 2001;10:75-81.
17. Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology 1996;14:437-42.
18. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in Augsburg elderly. Neurology 2000;54:1064-8.
19. Sukegawa T, Itoga M, Seno H, et al. Sleep disturbances and depression in the elderly in Japan. Psychiatry Clin Neurosci 2003;57:265-70.
20. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16:1159-63.
21. Sevim S, Dogu O, Kaleagasi H, Aral M, Metin O, Camdeviren H. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry 2004;75:226-30.
22. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000;160:2137-41.
23. Winkelmann J, Prager M, Lieb R, et al. "Anxietas Tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol 2005;252:67-71.
24. Vandeputte M, de Weerd A. Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 2003;4:343-5.
25. Saletu B, Anderer P, Saletu M, Hauer C, Lindeck-Pozza L, Saletu-Zyhlarz G. EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 2002; 3 Suppl: S35-42.
26. Bassetti CL, Mauerhofer D, Gugger M, Mathis J, Hess CW. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001;45:67-74.
27. Lee KA, Zaffke ME, Baratte-Beebe K. Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. J Womens Health Gend Based Med 2001;10:335-41.
28. Banno K, Delaive K, Walld R, Kryger MH. Restless legs syndrome in 218 patients: associated disorders. Sleep Med 2000;1:221-9.
29. Mosko S, Zetin M, Glen S, et al. Self-reported depressive symptomatology, mood ratings, and treatment outcome in sleep disorders patients. J Clin Psychol 1989;45:51-60.
30. Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004;5:309-15.
31. Tanaka K, Morimoto N, Tashiro N, Hori K, Katafuchi R, Fujimi S. The features of psychological problems and their significance in patients on hemodialysis-with reference to social and somatic factors. Clin Nephrol 1999;51:161-76.
32. Gorman CA, Dyck PJ, Pearson JS. Symptom of restless legs. Arch Intern Med 1965;115:155-60.
33. Young JR, Humphries AW, DeWolfe VG. Restless leg syndrome. Geriatrics 1969;24:167-71.
34. Leutgeb U, Martus P. Regular intake of non-opioid analgesics is associated with an increased risk of restless legs syndrome in patients maintained on antidepressants. Eur J Med Res 2002;7:368-78.
35. Saletu M, Anderer P, Saletu-Zyhlarz G, Hauer C, Saletu B. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 2002;252:185-94.
36. Saletu M, Anderer P, Högl B, et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm 2003;110:611-26.
37. Aikens JE, Vanable PA, Tadimeti L, Caruana-Montaldo B, Mendelson WB. Differential rates of psychopathology symptoms in periodic limb movement disorder, obstructive sleep apnea, psychophysiological insomnia, and insomnia with psychiatric disorder. Sleep 1999;22:775-80.
38. Mendelson WB. Are periodic leg movements associated with clinical sleep disturbance? Sleep 1996;19:219-23.
39. Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 2004;56:497-502.
40. Reynolds CF, 3rd, Coble PA, Spiker DG, Neil JF, Holzer BC, Kupfer DJ. Prevalence of sleep apnea and nocturnal myoclonus in major affective disorders: clinical and polysomnographic findings. J Nerv Ment Dis 1982;170:565-7.
41. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-54.
42. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci 1996;142:151-2.
43. Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand 1996;94:482-4.
44. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997;58:348-50.
45. Paik IH, Lee C, Choi BM, Chae YL, Kim CE. Mianserin-induced restless legs syndrome. Br J Psychiatry 1989;155:415-7.
46. Markkula J, Lauerma H. Mianserin and restless legs. Int Clin Psychopharmacol 1997;12:53-8.
47. Terao T, Terao M, Yoshimura R, Abe K. Restless legs syndrome induced by lithium. Biol Psychiatry 1991;30:1167-70.
48. Yang C, Winkelman JW, White DP. The effects of antidepressants on leg movements. Sleep 2004;27(Suppl 2):A311.
49. Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005;In Press.
50. Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology 1995;12:159-65.
51. Armitage R, Emslie G, Rintelmann J. The effect of fluoxetine on sleep EEG in childhood depression: a preliminary report. Neuropsychopharmacology 1997;17:241-5.
52. Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976;54:71-87.
53. Evidente VG, Caviness JN. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology 1999;52:211-3.
54. Patterson JF. Myoclonus caused by a tricyclic antidepressant. South Med J 1990;83:463-5.
55. Garvey MJ, Tollefson GD. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987;44:269-72.
56. Casas M, Garcia-Ribera C, Alvarez E, Udina C, Queralto JM, Grau JM. Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine. Int Clin Psychopharmacol 1987;2:333-6.
57. Morgan JL, Brown TM, Wallace ERt. Monoamine oxidase inhibitors and sleep movements. Am J Psychiatry 1994;151:782.
58. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
59. Nofzinger EA, Fasiczka A, Berman S, Thase ME. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000;61:858-62.
60. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Application. Cambridge: Cambridge University Press; 2000:xii:601.
61. 61; Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:249-60.
62. Shen J, Kennedy SH, Levitan RD, Kayumov L, Shapiro CM. The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. J Psychiatry Neurosci 2005;30:11-6.
63. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84.
64. Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 1997;146:105-14.
65. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-8.
66. Addington AM, Gallo JJ, Ford DE, Eaton WW. Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981-1994. Psychol Med 2001;31:1037-44.
67. Bruce ML. Psychosocial risk factors for depressive disorders in late life. Biol Psychiatry 2002;52:175-84.
68. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39-47.
69. VonKorff M, Simon GE. The relationship between pain and depression. Br J Psychiatry Suppl 1996;30:101-8.
70. Hening WA, Walters AS, Wagner M, et al. Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep 1999;22:901-12.
71. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18:128-47.
72. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61:304-9.
73. de Mello MT, Lauro FA, Silva AC, Tufik S. Incidence of periodic leg movements and of the restless legs syndrome during sleep following acute physical activity in spinal cord injury subjects. Spinal Cord 1996;34:294-6.
74. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63:7-8.
75. Damsa C, Bumb A, Bianchi-Demicheli F, et al. "Dopamine- dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004;65:1064-8.
76. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci 2003;73:3175-9.
77. Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry 2003;64 Suppl 13:13-7.
78. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004;5:385-91.
79. Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson's disease. J Neurol 2004;251 Suppl 6:VI/24-7.
80. Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res 1997;769:135-40.
81. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.
82. Waehrens J, Gerlach J. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. J Affect Disord 1981;3:193-202.
83. Dailly E, Chenu F, Renard CE, Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004;18:601-7.
84. Gallo JJ, Rabins PV. Depression without sadness: alternative presentations of depression in late life. Am Fam Physician 1999;60:820-6.
85. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.
86. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137-40.
87. Paluska SA, Schwenk TL. Physical activity and mental health: current concepts. Sports Med 2000;29:167-80.
88. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001;35:1608-13.
89. Shulman R. Response versus remission in the treatment of depression: understanding residual symptoms. Primary Psychiatry 2001;8:28-34.
90. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61 Suppl 2:20-5.
91. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004;65:337-40.
92. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001;25:131-8.
93. Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001;62:776-81.
94. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000;343:1942-50.
95. Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptom-specific? J Clin Psychiatry 2003;64:516-23.
96. Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med 2004;5:485-8.
97. Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004;61:1393-7.
98. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14.
99. Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 2004;5:15-20.
100. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-72.
101. Neylan TC. Treatment of sleep disturbances in depressed patients. J Clin Psychiatry 1995;56 Suppl 2:56-61.
102. Becker PM. Trazodone as a hypnotic in major depression. Sleep Med 2004;5:7-8.
103. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634-42.
104. International Classification of Sleep Disorders: Diagnostic and Coding Manual, revised. Rochester, MN: American Sleep Disorders Association; 1997:401.